BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

LifeScience Antibody Drug Conjugates

WuXi XDC H1 2026 Revenue Jumps 37% to RMB 3.7 Bn on Strong Bioconjugate Demand

Group total revenue increased to RMB 3,701.4 million, representing 37.0% period-over-period growth on an AER[1] basis (41.5% growth on a CER[2]...

August 26, 2026 | Company results

Akeso Secures China Clinical Trial Clearance for B7-H3 ADC AK157D1

Akeso, Inc. announced that its investigational next-generation B7-H3-targeting antibody-drug conjugate (ADC), AK157D1, has received clinical trial clearanc...

August 24, 2026 | News

Henlius, Sandoz Expand Global Biosimilars Alliance with Up to 10 New Antibody Assets

Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs...

August 18, 2026 | News

Biocon Launches Interchangeable YESAFILI Biosimilar to EYLEA in the U.S.

Yesafili™ (aflibercept-jbvf) now available in the United States as an U.S. FDA-approved interchangeable biosimilar to EYLEA 2 mg Potential ...

August 06, 2026 | News

Kelun-Biotech's TROP2 ADC sac-TMT Advances Toward First-Line TNBC Approval in China

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that a new indication application of its trophoblas...

August 03, 2026 | News

AsymBio Breaks Ground on Shanghai R&D Hub to Accelerate Biologics Development

AsymBio, a biologics-focused Contract Development and Manufacturing Organization (CDMO) and a subsidiary of Asymchem Group (stock codes: 002821.S...

July 29, 2026 | News

Biointron Launches RushData to Accelerate AI-Driven Antibody Discovery with High-Throughput Experimental Validation

1-day CHO expression for data generation in days, not weeks, for standardized, structured datasets ready for AI/ML-driven design Custom workflows for ...

July 28, 2026 | News

ArkBio Completes Dosing in Phase I Trial of Long-Acting Influenza Prevention Candidate AK0406

Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that all cohorts of healthy volunteers have been dosed in an Australian Phase I trial w...

July 27, 2026 | News

Samsung Bioepis Secures Exclusive Commercial Rights to Nectin-4 ADC Candidate SBE303

Ÿ Under the agreement, Samsung Bioepis will obtain exclusive commercial licensing rights to SBE303, an ADC candidate currently in joi...

July 24, 2026 | News

Lonza and Engitix Partner to Advance Next-Generation ECM-Targeted ADCs

Lonza grants Engitix target-specific license for GlycoConnect®, HydraSpace® and SYNtecan E™ linker-payload technologies for ADC de...

July 22, 2026 | News

Akeso Doses First Patient in Phase II Trial of AK146D1–Ivonescimab Combination for Advanced NSCLC

Akeso, Inc. (9926.HK) (announced that the first patient has been dosed in a Phase II clinical study (AK146D1-201) evaluating its internally developed TROP2...

July 21, 2026 | News

Evonik and evitria Simplify CHO-Based Protein Production with Ready-to-Use Expression Kit

New ready-to-use protein expression kit now available eviCHO Expression Kit simplifies transient protein expression workflows and enables faster, ...

July 17, 2026 | News

Kelun-Biotech’s Sac-TMT–Keytruda Combination Outperforms Standard First-Line Therapy in Phase III Lung Cancer Trial

As a head-to-head Phase III trial comparing sac-TMT plus pembrolizumab with the first-line standard of care (immunotherapy plus chemotherapy), OptiTROP-L...

July 16, 2026 | News

Leads Biolabs' Opamtistomig Receives China's Priority Review for Advanced Neuroendocrine Cancer

Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that the biologics license application (BLA) for Op...

July 14, 2026 | News

Stay Connected